<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Atrial Fibrillation • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Atrial Fibrillation • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/atrial fibrillation/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/atrial fibrillation/" />

<link rel="stylesheet" href="/wiki/style.css" />

  </head>
  <body>
    <div
      class="fixed top-0 w-screen px-4 py-4 md:px-10 bg-slate-200 bg-opacity-90"
    >
    <div class="flex items-center justify-between max-w-6xl mx-auto">
      <a href="/wiki/" title="Home">
        <img src="/wiki/assets/avatar.png" class="w-10 h-10 " />
      </a>

      <nav class="flex space-x-2 uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>
    <div class="mx-auto">

    <div class="flex items-center justify-center max-w-full px-6 mt-32 mb-32">
      <div  class="prose"><h1>atrial fibrillation</h1>
<ul>
<li>related: <a href="/wiki/notes/tachycardia/">tachycardia</a>, <a href="/wiki/notes/Arrythmia/">Arrythmia</a>, <a href="/wiki/notes/Cardiology/">Cardiology</a></li>
<li>tag: #note</li>
</ul>
<hr>
<h2>epidemiology</h2>
<ul>
<li>most common sustained arrhythmia</li>
<li>affect more than 33 million persons worldwide</li>
<li>Lifetime risk for atrial fibrillation is 25% in patients older than 40 years.</li>
<li>Incidence is strongly associated with and increases with age.</li>
<li>10% of persons older than 80 years.</li>
<li>fivefold increased risk for stroke</li>
<li>increased risk for heart failure and dementia</li>
<li>Among patients aged 55 years and older who have a cryptogenic ischemic neurologic event, such as a stroke or transient ischemic attack, occult intermittent atrial fibrillation is thought to be present in up to 25% of cases, and 30-day ambulatory ECG monitoring is indicated for detection. If 30-day ambulatory monitoring is inconclusive, implantation of a cardiac monitor (loop recorder) is reasonable to optimize detection of silent atrial fibrillation.</li>
</ul>
<h2>risks</h2>
<ul>
<li>DM</li>
<li>obesity</li>
<li>HTN</li>
<li>CAD</li>
<li>HF</li>
<li>sleep apnea</li>
<li>smoking</li>
<li>alcohol consumption</li>
</ul>
<h2>Duration</h2>
<ul>
<li>paroxysmal: stops within 7 days</li>
<li>persistent: last for 7 days or more</li>
<li>long standing persistent: &gt; 1 year</li>
</ul>
<h2>Management</h2>
<h3>unstable</h3>
<ul>
<li>synchronized cardioversion: avoids R on T event and Vfib</li>
<li>unknown duration or &gt; 48 hours duration: initiate AC and continue for 4 weeks at least</li>
</ul>
<h3>stable</h3>
<ul>
<li>testing
<ul>
<li>TSH</li>
<li>sleep apnea</li>
<li>echocardiogram for valvular or structural heart disease, left atrial size</li>
</ul>
</li>
</ul>
<h3>Rate control</h3>
<ul>
<li>goal:
<ul>
<li>&lt;60</li>
<li>&lt;110 in pts without lower EF</li>
</ul>
</li>
</ul>
<h3>Rhythm control</h3>
<ul>
<li>pill-in-the-pocket approach: pts with infrequent afib and no structural heart disease
<ul>
<li>on BB/CCB</li>
<li>flecainide/propafenone: take at onset of episode</li>
</ul>
</li>
</ul>
<h3>Ablation</h3>
<ul>
<li>for symptomatic afib despite antiarrythmic</li>
<li>pulmonary vein isolation</li>
<li>AV nodal ablation: afib with tachycardia despite rate/rhythm control. Needs permanent pacemaker. Also will remain in afib afterwards and still need AC](##)</li>
</ul>
<h3>cardioversion</h3>
<ul>
<li>pharm cardioversion: pt without structural heart disease
<ul>
<li>can use Ibutilide: monitor on tele for 6 hours or until QTc return to baseline due to small risk of torsades</li>
</ul>
</li>
</ul>
<h2>anticoagulation</h2>
<h3>When to start</h3>
<ul>
<li>afib duration &lt; 48 hours or low risk for stroke/thrombus
<ul>
<li>preprocedural AC for men with chadsvasc more than 1 and women more than 2</li>
</ul>
</li>
<li>unclear duration or &gt; 48 hours
<ul>
<li>AC for 3 weeks before cardioversion</li>
<li>can use TEE prior to cardioversion</li>
</ul>
</li>
<li>Continue at least 4 weeks following cardioversion due to increased risk for thrombus formation after sinus rhythm</li>
</ul>
<h3>Valvular vs Nonvalvular</h3>
<ul>
<li>non-valvular afib: base on CHA2DS2-VASc
<ul>
<li>men: AC if score ≥ 2</li>
<li>women: AC if score ≥ 3</li>
<li>other valves: aortic valve, MR, TR, mild mitral stenosis</li>
<li>can use non-vitamin K antagonist (NOAC)</li>
</ul>
</li>
<li>valvular afib: needs AC
<ul>
<li>mechanical prosthesis (mechanical valve replacement)</li>
<li>moderate to severe MS</li>
<li>cannot use NOAC, only warfarin</li>
</ul>
</li>
<li>Pt with HAS-BLED ≥ 3 needs regular evaluation</li>
</ul>
<h3>Agents</h3>
<ul>
<li>Warfarin
<ul>
<li>INR goal 2-3</li>
</ul>
</li>
<li>NOAC
<ul>
<li>kidney/liver function, reevaluate at least annually</li>
<li>dabigatran: thrombin inhibitor, Pradaxa
<ul>
<li>less intracranial bleed</li>
<li>higher GI bleed</li>
<li>dyspepsia</li>
</ul>
</li>
<li>rivaroxaban: 10a inhibitor, Xarelto
<ul>
<li>noninferior to warfarin with stroke or embolism</li>
<li>less intracranial/fatal bleed</li>
<li>higher GI bleed risk</li>
</ul>
</li>
<li>apixaban: 10a inhibitor, Eliquis
<ul>
<li>superior for stroke prevention</li>
<li>less major bleed risk</li>
<li>less intracranial bleed risk</li>
</ul>
</li>
<li>edoxaban:
<ul>
<li>noninferior for stroke prevention</li>
<li>less major bleed</li>
</ul>
</li>
<li>reversal agents
<ul>
<li>andexanet alfa or 4-factor PCC: for life-threatening bleed 2/2 10a inhibitors</li>
<li>Idarucizumab: for dabigatran, emergency invasive procedures or life threatening bleeds</li>
</ul>
</li>
</ul>
</li>
<li>left atrial appendage occlusion: can consider in pt with CHADSVASC ≥ 3
<ul>
<li>lower risk for intracranial bleed</li>
</ul>
</li>
<li>for pts with afib s/p PCI and CHADSVASC ≥ 2
<ul>
<li>double therapy: clopidogrel/ticagrelor + AC</li>
<li>better than triple therapy to reduce risk of bleed</li>
</ul>
</li>
<li>for pts with afib and stable CAD
<ul>
<li>xarelto alone instead ASA + rivaroxaban</li>
</ul>
</li>
</ul>
</div>
      
    </div>

    <div class="max-w-4xl mx-auto prose">
                  <hr />
<p>Backlinks</p>


<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/tachycardia/" class="peer">Tachycardia</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>tachycardia</h1>
<ul>
<li>related: <a href="/wiki/notes/Arrythmia/">Arrythmia</a></li>
<li>tags: #note</li>
</ul>
<hr>
<h2>Narrow Complex Tachycardia</h2>
<ul>
<li><a href="/wiki/notes/multifocal%20atrial%20tachycardia/">multifocal atrial tachycardia</a></li>
<li><a href="/wiki/notes/sinus%20tachycardia/">sinus tachycardia</a></li>
<li><a href="/wiki/notes/atrial%20fibrillation/">atrial fibrillation</a></li>
<li><a href="/wiki/notes/atrial%20flutter/">atrial flutter</a></li>
<li><a href="/wiki/notes/SVT/">SVT</a></li>
</ul>
<h2>Wide Complex tachycardia</h2>
<p>A wide-complex tachycardia is any tachycardia with a QRS complex of 120 ms or greater. Differential diagnoses include SVT with aberrancy, preexcited tachycardia (antidromic tachycardia), ventricular paced rhythm, and VT.</p>
<ul>
<li><a href="/wiki/notes/vtach/">vtach</a></li>
<li>[[PVC]</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-4xl mb-10 text-sm text-center mt-96 ">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
